GCTKHealthcare · Medical Devices

GCTK Stock Forecast: GlucoTrack, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026

$0.41

−13.02% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 11 of 100 as at 1 Aug 2026 — in the weakest quartile.

Market cap

$3.1M

Ticker Nerd rank

11 / 100

Median analyst target

—

Analysts covering

—

Total return, dividends reinvested

+36.5%

+29.7%

YTD

−89.3%

−93.3%

From 52W high

−96.1%

From 52W low

+45.6%

$11

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

GCTK stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores GlucoTrack, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026

11 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Growth

Accruals

Revisions

Momentum

Volatility

Value

Quality

Issuance

Size (97): Smaller than most of the companies we track.

Issuance (2): The company has been issuing shares or taking on financing, diluting existing holders.

The rank is the raw material. Whether the rules would actually own GlucoTrack, Inc. — and when they’d sell — is the membership.

Wall Street

GCTK stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GCTK, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

GCTK analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

GlucoTrack, Inc. (GCTK) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 0.1×
Price / sales: —
Price / book: −0.9×
EV / EBITDA: −0.2×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: −527.2%
Return on assets: −150.3%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

GCTK vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices

Company	Market cap	TKN rank
GCTKGlucoTrack, Inc.	$3.1M	11
XAIRBeyond Air, Inc.	$3.8M	27
TNONTENON Medical, Inc.	$3.4M	46
AMIXAutonomix Medical, Inc.	$3.3M	14
INBSIntelligent Bio Solutions, Inc.	$4.3M	10
BMRABiomerica, Inc.	$4.5M	35
ITOCiTonic Holdings Ltd.	$4.6M	23

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GCTK appears on the weeks it earns a place.

News

Latest GCTK news & analysis

Lōkahi Therapeutics™ ai² Futures Lab™ Changes How Biopharma Builds a Pipeline

Business Wire · 31 July 2026positive

Glucotrack, through its subsidiary Lōkahi Therapeutics, announced the continued expansion of its ai² Futures Lab, which identified over 45 therapeutic opportunities on a budget of roughly $33,000 in its first year and advanced five into active company discussions.

Why it matters — A GCTK watcher would care because the ai² Futures Lab is generating a substantial pipeline of therapeutic opportunities with very low capital expenditure, potentially creating value from prior biopharmaceutical investments totaling over $500 million.

Lōkahi Therapeutics™ Advances LT-100 Development Strategy Toward Single-Injection Administration

Business Wire · 29 July 2026positive

Glucotrack subsidiary Lōkahi Therapeutics announced progress in its LT-100 development strategy toward a single subcutaneous injection per visit, replacing a historical approach requiring up to 15 intradermal injections. The company discussed this during a Type C meeting with the FDA in May 2026.

Why it matters — A simplified single-injection regimen could meaningfully improve the commercial viability and patient adoption of LT-100, directly impacting the value of Glucotrack's pipeline asset.

FAQ

Frequently asked questions about GCTK stock

How does Ticker Nerd's model rank GCTK?

As at 1 Aug 2026, GlucoTrack, Inc. ranks 11 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (97 of 100).

What is the GCTK stock forecast for 2030?

No analyst covering GlucoTrack, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GCTK are extrapolating price history, which says nothing about the business.

How has GCTK stock performed over the past year?

GlucoTrack, Inc. returned -93.3% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does GlucoTrack, Inc. do?

Glucotrack Inc. is a company dedicated to developing non-invasive glucose monitoring technology.

What is the latest news on GCTK?

The most recent item we track (Business Wire, 31 July 2026): "Lōkahi Therapeutics™ ai² Futures Lab™ Changes How Biopharma Builds a Pipeline". Glucotrack, through its subsidiary Lōkahi Therapeutics, announced the continued expansion of its ai² Futures Lab, which identified over 45 therapeutic opportunities on a budget of roughly $33,000 in its first year and advanced five into active company discussions.

Company

About GlucoTrack, Inc.

Glucotrack Inc. is a company dedicated to developing non-invasive glucose monitoring technology. The core purpose of the company is to provide an alternative method for individuals with diabetes to track their blood glucose levels without the need for frequent finger-prick tests. This innovation primarily serves the healthcare and biotechnology sectors, offering a user-friendly solution that aims to improve patient comfort and compliance. The Glucotrack device is designed to measure glucose levels using several physiological parameters detected via an ear clip, conveying real-time data that can be crucial for metabolic management. Its focus on non-invasive technology positions it as a potential game-changer in the realm of diabetic care, especially considering the global prevalence of diabetes. In the broader market context, Glucotrack Inc. represents a significant development within the medtech industry, with its efforts reflecting an ongoing trend towards more patient-centered, convenient healthcare solutions. Its contribution lies not only in its innovative approach but also in its potential to reduce the physical and psychological barriers associated with traditional glucose monitoring methods.

CEO Dr. Paul V. Goode Ph.D. · 15 employees · United States · https://glucotrack.com